Skip to main content
main-content

01.09.2020 | Evidence-Based Medicine, Clinical Trials and Their Interpretations (L. Roever,Section Editor) | Ausgabe 9/2020

Current Atherosclerosis Reports 9/2020

Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis

Zeitschrift:
Current Atherosclerosis Reports > Ausgabe 9/2020
Autoren:
Marco Lombardi, Juan G. Chiabrando, Giovanni M. Vescovo, Edoardo Bressi, Marco Giuseppe Del Buono, Salvatore Carbone, Rachel A. Koenig, Benjamin W. Van Tassell, Antonio Abbate, Giuseppe Biondi-Zoccai, Dave L. Dixon
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s11883-020-00865-5) contains supplementary material, which is available to authorized users.
This article is part of the Topical Collection on Evidence-Based Medicine, Clinical Trials and Their Interpretations

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose of Review

Omega-3 fatty acid (O3FA) supplementation has shown conflicting evidence regarding its benefit in cardiovascular events. We performed a pairwise and network meta-analysis to elucidate the benefit of different doses of O3FA supplementation in cardiovascular prevention.

Recent Findings

Fourteen studies were identified providing data on 125,763 patients. A prespecified cut-off value of < 1 g per day was set for low-dose (LD) O3FA and > 1 g per day for high-dose (HD) O3FA. The efficacy outcomes of interest were total death, cardiac death, sudden cardiac death, myocardial infarction, stroke, coronary revascularization, unstable angina, and major vascular events. Safety outcomes of interest were bleeding, gastrointestinal disturbances, and atrial fibrillation events. HD treatment was associated with a lower risk of cardiac death (IRR 0.79, 95% CI [0.65–0.96], p = 0.03 versus control), myocardial infarction (0.71 [0.62–0.82], p < 0.0001 versus control and 0.79 [0.67–0.92], p = 0.003 versus LD), coronary revascularization (0.74 [0.66–0.83], p < 0.0001 versus control and 0.74 [0.66–0.84], p < 0.0001 versus LD), unstable angina (0.73 [0.62–0.86], p = 0.0001 versus control and 0.74 [0.62–0.89], p = 0.002 versus LD), and major vascular events (0.78 [0.71–0.85], p < 0.0001 versus control and 0.79 [0.72–0.88], p < 0.0001 versus LD). HD treatment was associated with increased risk for bleeding events (1.49 [1.2–1.84], p = 0.0002 versus control and 1.63 [1.16–2.3], p = 0.005 versus LD) and increased atrial fibrillation events compared to control (1.35 [1.1–1.66], p = 0.004).

Summary

HD O3FA treatment was associated with lower cardiovascular events compared to LD and to control, but increased risk for bleeding and atrial fibrillation events.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Zusatzmaterial
Nur für berechtigte Nutzer zugänglich
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2020

Current Atherosclerosis Reports 9/2020 Zur Ausgabe

Coronary Heart Disease (S. Virani and S. Naderi, Section Editor)

Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?

Women and Ischemic Heart Disease (P. Kohli, Section Editor)

Spontaneous Coronary Artery Dissection: Latest Developments and New Frontiers

Statin Drugs (R. Ceska, Section Editor)

The Role of Statins in Current Guidelines

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise